Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors

Over half of patients with BRCA1-deficient cancers do not respond to treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. In this study, we report that a combination of 53BP1 and BRCA1 may serve as a biomarker of PARP inhibitor sensitivity. Based on the mRNA levels of four homologous recomb...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Acta Pharmacol Sin
Egile Nagusiak: Yang, Zhong-min, Liao, Xue-mei, Chen, Yi, Shen, Yan-yan, Yang, Xin-ying, Su, Yi, Sun, Yi-ming, Gao, Ying-lei, Ding, Jian, Zhang, Ao, He, Jin-xue, Miao, Ze-hong
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2017
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519258/
https://ncbi.nlm.nih.gov/pubmed/28414200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2017.8
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak